SCHEMBL1642959

SCHEMBL1642959

O=C(CCCCC(=O)ON1CCNCC1)ON1CCNCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 5/20 0.38
GNAO1 P09471 5/20 0.38
GNAI1 P63096 5/20 0.38
CA2 P00918 2/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
CHKA P35790 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
CHRNB3 Q05901 1/20 0.32
CHRNA6 Q15825 1/20 0.32
HRH2 P25021 1/20 0.32
HRH1 P35367 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
CHRM5 P08912 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8581907 0.98 GNAI3 (0.40) GNAI3GNAO1GNAI1CA2CA12
SCHEMBL5875102 0.98 GNAI3 (0.40) GNAI3GNAO1GNAI1CA2CA12
SCHEMBL5875158 0.96 TSHR (0.34) GNAI3GNAO1GNAI1CA2CA12
SCHEMBL28251269 0.93 ITGB3 (0.41) GNAI3GNAO1GNAI1ITGB3ITGA2B
SCHEMBL5008157 0.91 CA2 (0.37) GNAI3GNAO1GNAI1CA2CA12
SCHEMBL5874316 0.91 GNAI3 (0.50) GNAI3GNAO1GNAI1SIGMAR1HRH2
SCHEMBL27888271 0.90 CAMK2A (0.32) GNAI3GNAO1GNAI1CA2CA12
SCHEMBL5874398 0.89 GNAI3 (0.53) GNAI3GNAO1GNAI1SIGMAR1HRH2
SCHEMBL5875251 0.89 GNAI3 (0.53) GNAI3GNAO1GNAI1SIGMAR1HRH2
SCHEMBL5874232 0.89 GNAI3 (0.53) GNAI3GNAO1GNAI1SIGMAR1HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240122859-A1 EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION NOKHA TRADING LLP (IN) 2024-04-18 US claimed
WO-2022172225-A1 EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION LYRUS LIFE SCIENCES PVT. LTD. (IN) 2022-08-18 WO claimed
US-20170135347-A1 INSECTICIDAL, MITICIDAL, NEMATICIDAL, MOLLUSCICIDAL, MICROBICIDAL, OR BACTERICIDAL COMPOSITION AND METHOD FOR CONTROLLING PEST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-05-18 US claimed
CN-106659160-A Insecticide, miticide, nematicide, molluscicide, disinfectant, or bactericide composition, and pest control method 日产化学工业株式会社 2017-05-10 CN claimed
EP-2496089-B1 AGENT FOR EXPELLING PARASITES IN HUMANS, ANIMALS OR BIRDS MEIJS MARIA WILHELMINA (BE) 2017-02-22 EP claimed
CN-104125774-A Pest control composition comprising novel iminopyridine derivatives MEIJI SEIKA PHARMA CO LTD 2014-10-29 CN claimed
US-20140315839-A1 PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-10-23 US claimed
US-8709440-B2 Agent for expelling parasites in humans, animals or birds MOMENTUM ANIMAL CURE BVBA (BE) 2014-04-29 US claimed
WO-2013129688-A1 PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2013-09-06 WO claimed
EP-2633756-A1 Pest control composition including novel iminopyridine derivate Meiji Seika Pharma Co., Ltd. (JP) 2013-09-04 EP claimed
US-20120231032-A1 AGENT FOR EXPELLING PARASITES IN HUMANS, ANIMALS OR BIRDS MEIJS, M.W. (BE) 2012-09-13 US claimed
CN-102325451-A Composition to control harmful organisms that contains 16-keto aspergillimide MEIJI SEIKA KAISHA 2012-01-18 CN claimed
US-20110263520-A1 COMPOSITION FOR USE IN CONTROLLING HARMFUL ORGANISMS THAT CONTAINS 16-KETO ASPERGILLIMIDE MEIJI SEIKA PHARMA CO., LTD. (JP) 2011-10-27 US claimed
EP-2380439-A1 COMPOSITION TO CONTROL HARMFUL ORGANISMS THAT CONTAINS 16-KETO ASPERGILLIMIDE Meiji Seika Pharma Co., Ltd. (JP) 2011-10-26 EP claimed
EP-1599190-A2 CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF Glenmark Pharmaceuticals Limited (IN) 2005-11-30 EP claimed
US-20040185097-A1 Controlled release modifying complex and pharmaceutical compositions thereof GLENMARK PHARMACEUTICALS LTD. 2004-09-23 US claimed
WO-2004066910-A2 CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF GLENMARK PHARMACEUTICALS LTD. (US) 2004-08-12 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315839-A1 PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE API5, DDT, INTS9 GNAI3 3164/4885GNAO1 3384/4885GNAI1 2810/4885
US-20110263520-A1 COMPOSITION FOR USE IN CONTROLLING HARMFUL ORGANISMS THAT CONTAINS 16-KETO ASPERGILLIMIDE MGAM, CYP51A1, AKR7A2 GNAI3 3175/4885GNAO1 3489/4885GNAI1 3068/4885
US-20170135347-A1 INSECTICIDAL, MITICIDAL, NEMATICIDAL, MOLLUSCICIDAL, MICROBICIDAL, OR BACTERICIDAL COMPOSITION AND METHOD FOR CONTROLLING PEST DDT, ACHE, DRD5 GNAI3 3896/4885GNAO1 4151/4885GNAI1 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.